As of May 29, 2025, Emerald Health Therapeutics Inc (EMH.CN) reports a ROE (Return on Equity) of -116.40%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Emerald Health Therapeutics Inc's ROE (Return on Equity)
Over recent years, Emerald Health Therapeutics Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -116.40% |
| 2020-12-31 | -58.47% |
| 2019-12-31 | -106.94% |
| 2018-12-31 | -17.93% |
| 2017-12-31 | -13.26% |
This slight downward trend highlights how Emerald Health Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Emerald Health Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Emerald Health Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Emerald Health Therapeutics Inc (EMH.CN) | -116.40% |
| Cronos Group Inc (CRON.TO) | 3.86% |
| Bausch Health Companies Inc (BHC.TO) | 3.60% |
| Aphria Inc (APHA.TO) | -4.67% |
| Tilray Brands Inc (TLRY) | -7.12% |
| SNDL Inc (SNDL) | -8.36% |
Compared to its competitors, Emerald Health Therapeutics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.